ADVM

Adverum Biotechnologies, Inc. [ADVM] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ADVM Stock Summary

Top 10 Correlated ETFs

ADVM

Top 10 Correlated Stocks

ADVM

In the News

ADVM Financial details

Company Rating
-
Market Cap
243.45M
Income
-117.17M
Revenue
3.6M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
121
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.74
Forward P/E
-
PEG
0.29
P/S
25.82
P/B
0.9
P/C
-
P/FCF
-1.05
Quick Ratio
4.06
Current Ratio
4.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-11.63
EPS next Y
-
EPS next Q
-
EPS this Y
-25.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
2.93%
Revenue last 5Y
70.48%
Revenue Q/Q
-
EPS Q/Q
-28.22%
-
-
-
-
SMA20
25%
SMA50
25%
SMA100
-37.5%
Inst Own
-
Inst Trans
-
ROA
-64%
ROE
-88%
ROC
-0.78%
Gross Margin
100%
Oper. Margin
-3660%
Profit Margin
-3505%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.1-29.7
52W High
-86.84%
52W Low
-45.5%
RSI
38
Rel Volume
0.74
Avg Volume
281.64K
Volume
208.11K
Perf Week
-22.62%
Perf Month
-4.15%
Perf Quarter
-49.27%
Perf Half Y
-45.03%
-
-
-
-
Beta
0.793
-
-
Volatility
0.38%, 0.44%
Prev Close
-12.7%
Price
3.815
Change
-14.27%

Something similar

Top by Market Cap
MSFT
AVGO
1YD.DE
BRK-A
AAPL
Top Correlated ETFs
VXM.TO
EWJV
PJEU.DE
C051.DE
ERNA.L
Top Correlated Stocks
002289.SZ
PTCT
0124.HK
0902.HK
605005.SS
Similar Market Cap
FDHY
EAFGX
UKCO.L
TOAC
HQU.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 281.64K
  • Market Capitalization 243.45M
  • Employee 121
  • CEO Dr. Laurent Fischer
  • Headquarters Redwood City,CA,US
  • IPO Date 2014-07-31
  • Website https://www.adverum.com

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.